How Verismo’s multi-chain KIR-CAR platform differs from conventional CAR-T
Verismo Therapeutics has disclosed an 80% objective response rate among five evaluable lymphoma patients treated with SynKIR-310 in its first two dose cohorts. No cytokine release syndrome, neurotoxicity or dose-limiting toxicity was reported among six treated patients, but the findings remain preliminary ahead of expanded data scheduled for December.